12 completed, 5 unknown, 2 recruiting, 2 terminated. 22 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 22 | Completed 12, Unknown 5, Recruiting 2, Terminated 2, Not yet recruiting 1 |
Follow Febuxostat: new trials by email Literature Review of Febuxostat trials Research Report on Febuxostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat - Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis | Phase 4 | Not yet recruiting | Haiphong University of Medicine and Pharmacy | 228 | 2026-01-20 | 2026-01-27 |
| the Effects of Febuxostat Dose Tapering in Gout Patients Optimally Controlled for 5 Years or More Febuxostat - Gout, Uric Acid | Phase 4 | Recruiting | Seoul National University Hospital | 59 | 2025-09-10 | 2026-04-29 |
| Effect of Dotinurad in Hyperuricemia With Hypertension Dotinurad, Febuxostat - Hyperuricemia or Gout, Hypertension | Phase 4 | Recruiting | Saga University | 360 | 2025-03-28 | 2025-12-15 |
| Febuxostat Versus Allopurinol on Hepatic Steatosis in MAFLD Patients Allopurinol (100 mg/day) plus lifestyle intervention, Febuxostat 40 mg plus lifestyle intervention, Life style intervention - Non-Alcoholic Fatty Liver Disease, Hyperuricemia | Phase 4 | Completed | Ain Shams University | 90 | 2022-01-01 | 2023-08-01 |
| A Randomized Clinical Trail of The Effect of Postoperative Uric Acid Control on Stone Recurrence and Renal Function in Patients With Hyperuricemia of Urolithiasis. Febuxostat 40mg Tab, Non-drug control group - Hypouricemia, Renal, Urolithiasis | Phase 4 | Unknown | Xuhui Central Hospital, Shanghai | 100 | 2020-04-10 | 2020-05-21 |
| Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction Febuxostat 40 mg, Benzbromarone 50mg, Control - Hyperuricemia, Metabolic Syndrome | Phase 4 | Unknown | National Defense Medical Center, Taiwan | 120 | 2020-02-01 | 2020-04-28 |
| The Impact of Urate-lowering Therapy on Kidney Function (IMPULsKF) Febuxostat 80 MG Oral Tablet or Allopurinol 300 MG Oral Tablet - Gout, CKD Stage 1-4 | Phase 4 | Unknown | Medical Practice Prof D. Ivanov | 2 | 2017-10-30 | 2022-08-24 |
| A Phase 4 Safety and Efficacy Study to Evaluate Lesinurad 200 mg in Participants With Gout and Renal Impairment Lesinurad, XOI, Placebo - Gout, Chronic Kidney Disease (CKD) | Phase 4 | Terminated | Ironwood Pharmaceuticals, Inc. | 242 | 2017-07-19 | 2021-11-04 |
| Lowering-hyperuricemia Treatment on Cardiovascular Outcomes in Peritoneal Dialysis Patients Febuxostat, Placebo - Hyperuricemia | Phase 4 | Unknown | Sun Yat-sen University | 548 | 2017-07-11 | 2020-10-22 |
| CSP594 Comparative Effectiveness in Gout: Allopurinol vs. Febuxostat allopurinol capsule, 100-800 mg by mouth once daily, febuxostat tablet 40-120 mg by mouth once daily, Placebo, vehicle control (febuxostat-shaped) - Gout, Chronic Kidney Diseases | Phase 4 | Completed | VA Office of Research and Development | 950 | 2017-03-06 | 2024-03-29 |
| Effect of Hyperuricaemia on Chronic Renal Disease 20mg Febuxostat, 40mg Febuxostat - Hyperuricemia, Chronic Renal Disease | Phase 4 | Unknown | The Affiliated Hospital of Xuzhou Medical University | 400 | 2017-01-01 | 2018-02-07 |
| Intensive Urate Lowering Therapy of Febuxostat Compared to Allopurinol on Cardiovascular Risk in Patients With Gout Febuxostat 80/120mg/day, Allopurinol 100 up to 600mg/day, Colchicine - Gout | Phase 4 | Completed | Menarini International Operations Luxembourg SA | 196 | 2015-08-17 | 2019-06-21 |
| the Effect of Febuxostat on Coronary Plaque Volume in Patients With Chronic Stable Angina and Hyperuricemia Febuxostat - Coronary Artery Disease | Phase 4 | Terminated | Yokohama City University Medical Center | 1 | 2014-10-01 | 2017-08-03 |
| Zurig (Febuxostat) 40mg Efficacy and Safety Trial Febuxostat, Allopurinol - Hyperuricemia | Phase 4 | Completed | Getz Pharma | 50 | 2013-11-01 | 2019-08-01 |
| The Influence of Febuxostat on Coronary Artery Endothelial Dysfunction in Participants With Chronic Stable Angina Febuxostat, Febuxostat placebo - Coronary Artery Disease | Phase 4 | Completed | Takeda | 30 | 2013-05-01 | 2016-04-13 |
| Effect of Allopurinol and Febuxostat on Urinary 2,8-Dihydroxyadenine Excretion Allopurinol, Febuxostat - Adenine Phosphoribosyltransferase Deficiency | Phase 4 | Completed | Landspitali University Hospital | 9 | 2013-05-01 | 2024-04-09 |
| Immune Molecular and Inflammatory Cytokines Dysfunction Analysis in Gout Patients With Different Urate Levels Diacerein, Colchicine, Febuxostat - Primary Gout | Phase 4 | Completed | Tongji Hospital | 96 | 2013-01-01 | 2014-05-08 |
| The Effect of Uric Acid Lowering in Type 1 Diabetes Febuxostat - Type 1 Diabetes Mellitus | Phase 4 | Completed | University Health Network, Toronto | 73 | 2012-12-18 | 2018-01-16 |
| Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome Febuxostat - Gout | Phase 4 | Completed | University of Texas Southwestern Medical Center | 24 | 2012-05-01 | 2023-03-14 |
| Study of Febuxostat Effect on Blood Pressure in Patients With High Normal Blood Pressure Febuxostat - Prehypertension, Gout | Phase 4 | Completed | University of California, San Diego | 47 | 2011-10-01 | 2019-12-16 |
Showing 20 of 22. Sign in to see all of them.
Gout (10) · Hyperuricemia (10) · Hypertension (3) · Renal Insufficiency, Chronic (3) · Cardiovascular Diseases (2) · Coronary Artery Disease (2) · Adenine phosphoribosyltransferase deficiency (1) · Arthritis (1) · Arthritis, Gouty (1) · Diabetes Complications (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 1 (1) · Diabetic Nephropathies (1) · Hyperglycemia (1) · Inflammation (1)
Ain Shams University (1) · Getz Pharma (1) · Haiphong University of Medicine and Pharmacy (1) · Ironwood Pharmaceuticals, Inc. (1) · Landspitali University Hospital (1) · Medical Practice Prof D. Ivanov (1) · Menarini International Operations Luxembourg SA (1) · National Defense Medical Center, Taiwan (1) · Paul N. Hopkins (1) · Saga University (1) · Seoul National University Hospital (1) · Sun Yat-sen University (1) · Takeda (1) · The Affiliated Hospital of Xuzhou Medical University (1) · Tongji Hospital (1)
United States (7) · China (4) · Japan (2) · Poland (2) · Canada (1) · Czechia (1) · Egypt (1) · Germany (1) · Hungary (1) · Iceland (1) · Italy (1) · Netherlands (1) · Pakistan (1) · Romania (1) · Serbia (1)
Cheng-Wei Liu, M.D. (1) · Claudio Borghi, Prof (1) · Daniel O'Connor, UCSD (1) · David ZI Cherney, MD, PhD (1) · Dong Sun, MD (1) · Ernesto J Rodriguez, MD (1) · James R O'Dell (1) · Jason T. Davis, M.D. (1) · JianMing Guo, PHD,M.D (1) · John D Carter, MD (1) · Khalid Mahmood, FCPS (1) · Kiyoshi Hibi, MD (1) · Koichi Node, Pr.,Dr. (1)
PMID 12421831, PMID 15698861, PMID 18349746, PMID 26724837, PMID 28408434, PMID 29447788, PMID 32877573, PMID 33040002, PMID 35434725, PMID 37842953, PMID 38260556, PMID 38766125, PMID 39426967
2014 (1), U54DK083908 (1)